Drug · DIN 02238337
REACTINE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 12, 2026; first marketed December 21, 1999.
- Drug Identification Number (DIN)
- 02238337
- Company (DIN owner)
- Kenvue Canada Inc.Guelph, Ontario, Canada
- Schedule
- Non-prescription drugs
- Dosage form
- Syrup
- Route
- Oral
- Therapeutic class (ATC)
- Cetirizine R06AE07
- Class
- Human
- Record last updated
- March 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CETIRIZINE HYDROCHLORIDE | 5 MG | 5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 12, 2026: NOC 37087New Drug Submission (NDS) · Administrative: Change in manufacturer name
- December 22, 2023: NOC 32428Supplement to a New Drug Submission (SNDS) · Safety update to the Product Monograph
- August 15, 2022: NOC 28758Supplement to a New Drug Submission (SNDS) · Update to the Product Monograph to comply with the 2020 PM template. Updates to Labelling Materials . Addition of packaging size
- January 23, 2007: NOC 8544New Drug Submission (NDS) · Manufacturer name change
- January 3, 2003: NOC 432New Drug Submission (NDS) · Manufacturer name change
- July 22, 1998: NOC 2763Supplement to a New Drug Submission (SNDS) · New dosage form
Other DINs named REACTINE
- DIN 02223546 · Marketed
- DIN 02223554 · Marketed